Medicinal treatment of retroperitoneal soft tissue sarcomas

被引：0

作者：

Falkenhorst, Johanna ^{[1
]}

Hamacher, Rainer ^{[1
]}

Bauer, Sebastian ^{[1
]}

机构：

[1] Univ Duisburg Essen, Univ Klinikum Essen, Sarkomzentrum amWestdeutschen Tumorzentrum, Hufelandstr 55, D-45147 Essen, Germany

来源：

CHIRURG | 2022年 / 93卷 / 01期

关键词：

Chemotherapy; Sarcoma; Leiomyosarcoma; Liposarcoma; Evidence; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; PROGNOSTIC-FACTORS; EWINGS-SARCOMA; MULTICENTER; SURVIVAL; OSTEOSARCOMA; EXTREMITIES; IFOSFAMIDE; THERAPY;

D O I：

10.1007/s00104-021-01539-x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Retroperitoneal soft tissue sarcomas represent extreme challenges for interdisciplinary treatment teams. The sarcoma-specific experience of surgeons has the greatest impact on the survival of patients; however, too many patients still die despite optimal local treatment. The role of chemotherapy is undisputed only for patients with highly malignant bone sarcomas or rhabdomyosarcomas. For soft tissue sarcomas in adult patients, especially liposarcomas and leiomyosarcomas, the evidence situation is very unsatisfactory. This overview article discusses the complex data situation and controversial aspects that are relevant for current treatment decisions in interdisciplinary treatment teams.

引用

页码：40 / 47

页数：8

共 32 条

[1] Adjuvant chemotherapy for soft tissue sarcoma? A clear no - well - yes-ish [J].

Abendroth, A. ;

Bauer, S. .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (41) :2107-2110

[2] Histology-Specific Nomogram for Primary Retroperitoneal Soft Tissue Sarcoma [J].

Ardoino, Ilaria ;

Miceli, Rosalba ;

Berselli, Mattia ;

Mariani, Luigi ;

Biganzoli, Elia ;

Fiore, Marco ;

Collini, Paola ;

Stacchiotti, Silvia ;

Casali, Paolo Giovanni ;

Gronchi, Alessandro .

CANCER, 2010, 116 (10) :2429-2436

[3] Medical Progress - Common musculoskeletal tumors of childhood and adolescence [J].

Arndt, CAS ;

Crist, WM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (05) :342-352

[4] Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies [J].

Bauer, Sebastian ;

Demetri, George D. ;

Halilovic, Ensar ;

Dummer, Reinhard ;

Meille, Christophe ;

Tan, Daniel S. W. ;

Guerreiro, Nelson ;

Jullion, Astrid ;

Ferretti, Stephane ;

Jeay, Sebastien ;

Van Bree, Laurence ;

Hourcade-Potelleret, Florence ;

Wuerthner, Jens U. ;

Fabre, Claire ;

Cassier, Philippe A. .

BRITISH JOURNAL OF CANCER, 2021, 125 (05) :687-698

[5] Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study [J].

Ben-Ami, Eytan ;

Barysauskas, Constance M. ;

Solomon, Sarah ;

Tahlil, Kadija ;

Malley, Rita ;

Hohos, Melissa ;

Polson, Kathleen ;

Loucks, Margaret ;

Severgnini, Mariano ;

Patel, Tara ;

Cunningham, Amy ;

Rodig, Scott J. ;

Hodi, F. Stephen ;

Morgan, Jeffrey A. ;

Merriam, Priscilla ;

Wagner, Andrew J. ;

Shapiro, Geoffrey I. ;

George, Suzanne .

CANCER, 2017, 123 (17) :3285-3290

[6] Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].

Bielack, SS ;

Kempf-Bielack, B ;

Delling, G ;

Exner, GU ;

Flege, S ;

Helmke, K ;

Kotz, R ;

Salzer-Kuntschik, M ;

Werner, M ;

Winkelmann, W ;

Zoubek, A ;

Jürgens, H ;

Winkler, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790

[7] Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial [J].

Bissler, John J. ;

Kingswood, J. Christopher ;

Radzikowska, Elzbieta ;

Zonnenberg, Bernard A. ;

Frost, Michael ;

Belousova, Elena ;

Sauter, Matthias ;

Nonomura, Norio ;

Brakemeier, Susanne ;

de Vries, Petrus J. ;

Whittemore, Vicky H. ;

Chen, David ;

Sahmoud, Tarek ;

Shah, Gaurav ;

Lincy, Jeremie ;

Lebwohl, David ;

Budde, Klemens .

LANCET, 2013, 381 (9869) :817-824

[8] NTRK fusion-positive cancers and TRK inhibitor therapy [J].

Cocco, Emiliano ;

Scaltriti, Maurizio ;

Drilon, Alexander .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :731-747

[9] Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group [J].

D'Ambrosio, Lorenzo ;

Touati, Nathan ;

Blay, Jean-Yves ;

Grignani, Giovanni ;

Flippot, Ronan ;

Czarnecka, Anna M. ;

Piperno-Neumann, Sophie ;

Martin-Broto, Javier ;

Sanfilippo, Roberta ;

Katz, Daniela ;

Duffaud, Florence ;

Vincenzi, Bruno ;

Stark, Daniel P. ;

Mazzeo, Filomena ;

Tuchscherer, Armin ;

Chevreau, Christine ;

Sherriff, Jenny ;

Estival, Anna ;

Litiere, Saskia ;

Sents, Ward ;

Ray-Coquard, Isabelle ;

Tolomeo, Francesco ;

Le Cesne, Axel ;

Rutkowski, Piotr ;

Stacchiotti, Silvia ;

Kasper, Bernd ;

Gelderblom, Hans ;

Gronchi, Alessandro .

CANCER, 2020, 126 (11) :2637-2647

[10] Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials [J].

D'Angelo, Sandra P. ;

Mahoney, Michelle R. ;

Van Tine, Brian A. ;

Atkins, James ;

Milhem, Mohammed M. ;

Jahagirdar, Balkrishna N. ;

Antonescu, Cristina R. ;

Horvath, Elise ;

Tap, William D. ;

Schwartz, Gary K. ;

Streicher, Howard .

LANCET ONCOLOGY, 2018, 19 (03) :416-426

← 1 2 3 4 →